Vis enkel innførsel

dc.contributor.authorJørgensen, Camilla Tøvik
dc.contributor.authorTavoly, Mazdak
dc.contributor.authorPettersen, Heidi Hassel
dc.contributor.authorFørsund, Eli
dc.contributor.authorRoaldsnes, Christina
dc.contributor.authorOlsen, Magnus Kringstad
dc.contributor.authorTjønnfjord, Eirik
dc.contributor.authorGleditsch, Jostein
dc.contributor.authorGalovic, Aleksandra Grdinic
dc.contributor.authorVikum, Synne Frønæs
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorGhanima, Waleed
dc.date.accessioned2022-11-15T11:33:14Z
dc.date.available2022-11-15T11:33:14Z
dc.date.issued2022-08-04
dc.description.abstractPurpose: The incidence of venous thromboembolism (VTE) is expected to increase over the next decades, further increasing its substantial impact on patients and health care resources. Registries have the benefit of reporting real-world data without excluding clinically important subgroups. Our aim was to describe a Norwegian VTE registry and to provide descriptive data on the population and management.<p> <p>Registry Population: The Venous Thrombosis Registry in Østfold Hospital (TROLL) is an ongoing registry of consecutive patients diagnosed with, treated, and/or followed up for VTE at Østfold Hospital, Norway, since 2005. Baseline and follow-up data, including demographics, clinical features, risk factors, diagnostic procedures, classification of VTE, and treatment were collected during hospitalization, and at scheduled outpatient visits. <p>Findings to Date: From January 2005 to June 2021, 5037 patients were eligible for research in TROLL. Median age was 67 years (interquartile range, 55–77), and 2622 (52.1%) were male. Of these, 2736 (54.3%) had pulmonary embolism (PE), 2034 (40.4%) had deep vein thrombosis (DVT), and 265 (5.3%) had upper-extremity DVT or splanchnic or cerebral sinus vein thrombosis. In total, 2330 (46.3%) were classified as unprovoked VTE, and 1131 (22.5%) had cancer. Direct oral anticoagulants were the most frequent therapeutic agents (39.3%) followed by low-molecular-weight heparins (30.4%) and vitamin K antagonists (30.3%). Outpatient treatment for PE increased from 4% in 2005 to 23% in 2019. <p>Future Plans: TROLL is a population-based ongoing registry that represents a valuable source of real-world data that will be used for future research on the management and outcomes of VTE.en_US
dc.identifier.citationJørgensen, Tavoly, Pettersen, Førsund, Roaldsnes, Olsen, Tjønnfjord, Gleditsch, Galovic, Vikum, Brækkan, Ghanima. The venous thrombosis registry in Østfold Hospital (TROLL registry) - design and cohort description. Research and Practice in Thrombosis and Haemostasis. 2022;6(5)en_US
dc.identifier.cristinIDFRIDAID 2059177
dc.identifier.doi10.1002/rth2.12770
dc.identifier.issn2475-0379
dc.identifier.urihttps://hdl.handle.net/10037/27376
dc.language.isoengen_US
dc.publisherWileyen_US
dc.relation.journalResearch and Practice in Thrombosis and Haemostasis
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0en_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)en_US
dc.titleThe venous thrombosis registry in Østfold Hospital (TROLL registry) - design and cohort descriptionen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Med mindre det står noe annet, er denne innførselens lisens beskrevet som Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)